Mr. Ahmad Doroudian reports

BETTERLIFE PHARMA ESTABLISHES SCIENTIFIC ADVISORY BOARD FOR HEADACHE PROGRAM; PROFESSOR PETER GOADSBY APPOINTED CO-CHAIR

Betterlife Pharma Inc. has formed a scientific advisory board to guide the clinical development of BETR-001. Prof. Peter Goadsby, MD, PhD, FRS, has been appointed co-chair.

The SAB will advise the company's management and board of directors on clinical development strategy, the design and conduct of its planned clinical studies in chronic cluster headache and chronic migraine, and the scientific basis for its interactions with regulators.

Prof. Goadsby is internationally recognized for research that has changed how headache in general and migraine in particular are understood and treated. His work identified calcitonin gene-related peptide as a central driver of migraine, research that led to an entirely new class of migraine-specific medicines now used by millions of patients. He was a co-recipient of the 2021 brain prize, the world's largest neuroscience award, and was elected a fellow of the Royal Society in 2022. His clinical and research career has spanned both migraine and cluster headache.

Prof. Goadsby currently serves as senior associate to the president and founding dean of the Division of Biomedical Sciences at King Abdullah University of Science and Technology. He also holds appointments as professor of neurology at King's College London, and honorary consultant neurologist at King's College Hospital and Great Ormond Street Hospital for Children, London. He is a National Institute for Health and Care Research emeritus senior investigator and emeritus professor of neurology at the University of California, Los Angeles. He previously held faculty positions at University College London, the National Hospital for Neurology and Neurosurgery, Queen Square, and the University of California, San Francisco.

"Chronic cluster headache is one of the most disabling conditions in neurology, and patients who do not respond to current preventive treatment have very few options," said Prof. Goadsby. "Progress in this field has always depended on asking precise clinical questions and designing studies that can answer them. I look forward to working with the Betterlife team as BETR-001 moves toward the clinic."

"Peter Goadsby helped build the modern science of headache medicine," said Douglas Drysdale, executive chair of Betterlife's board of directors. "We intend to use his judgment where it matters most: in how we design, run and interpret our studies. His deep insight and expertise in headache will be invaluable to us. Having him co-chair the SAB as we prepare our IND is a significant step for the program."

In connection with his appointment, the company has agreed to grant Prof. Goadsby stock options to purchase 500,000 common shares of Betterlife, with quarterly vesting over 24 months and a 10-year term. Exercise price for the stock options will be in accordance with the policies of the Canadian Securities Exchange.

About BETR-001

BETR-001 is a non-hallucinogenic derivative of 2-bromo-lysergic acid diethylamide in development for the preventive treatment of chronic cluster headache and chronic migraine. The company holds a granted U.S. composition-of-matter patent covering BETR-001. BETR-001 is an investigational product and has not been approved by any regulatory authority.

About Betterlife Pharma Inc.

Betterlife is an emerging biotechnology company primarily focused on developing and commercializing BETR-001 to treat various neurological disorders, such as chronic cluster headache and chronic migraine.

We seek Safe Harbor.